Keyphrases
BRAF mutation
100%
Ovarian Response
100%
Low-grade Serous Ovarian Cancer
100%
BRAF Inhibition
100%
Low-grade Serous Ovarian Carcinoma
100%
BRAF Inhibitor (BRAFi)
83%
Targeted Treatment
33%
Tumor Subtype
33%
BRAF V600E mutation
33%
Cancer Types
16%
Monotherapy
16%
Mitogen-activated Protein Kinase
16%
Patient Characteristics
16%
Treatment Outcome
16%
Response Rate
16%
Clinical Benefit
16%
Positron Emission Tomography
16%
Response to Treatment
16%
Effective Treatment
16%
Immunohistochemistry
16%
Sarcoma
16%
Disease Progression
16%
Chemotherapy
16%
Progressive Disease
16%
Type-specific
16%
Whole Genome Sequencing
16%
Follow-up Time
16%
Colorectal Cancer
16%
Targeted Sequencing
16%
Durable Response
16%
Activating mutation
16%
Conventional Chemotherapy
16%
Rare Tumors
16%
Carbohydrate Antigen 125 (CA125)
16%
Dabrafenib
16%
BRAF-mutant Melanoma
16%
Targeted Exome
16%
BRAF V600E
16%
Clinical Outcomes
16%
Biochemistry, Genetics and Molecular Biology
Exome
100%
Prospective Study
100%
Dabrafenib
100%
Whole Genome Sequencing
100%
Mitogen-Activated Protein Kinase
100%
Tumor Antigen
100%
Positron Emission Tomography
100%
Medicine and Dentistry
Ovarian Cancer
100%
Krukenberg Tumor
100%
Targeted Therapy
33%
Somatics
33%
Neoplasm
16%
Nodular Melanoma
16%
Patient Characteristics
16%
Immunohistochemistry
16%
Sarcoma
16%
Disease Exacerbation
16%
Prospective Study
16%
Colorectal Cancer
16%
Monotherapy
16%
Positron Emission Tomography
16%
Tumor Antigen
16%
Cancer Types
16%
Ras
16%
Rare Tumor
16%
Progressive Disease
16%
Dabrafenib
16%
Mitogen-Activated Protein Kinase
16%
Exome
16%
Whole Genome Sequencing
16%
Immunology and Microbiology
Mitogen
100%
Tumor Antigen
100%
Whole Genome Sequencing
100%
Positron Emission Tomography
100%
Exome
100%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Ovary Carcinoma
100%
Chemotherapy
33%
Neoplasm
33%
Prospective Study
16%
Mitogen Activated Protein Kinase
16%
Malignant Neoplasm
16%
Melanoma
16%
Disease Exacerbation
16%
Colorectal Cancer
16%
Dabrafenib
16%
Sarcoma
16%
Disease
16%
Tumor Antigen
16%
Monotherapy
16%